MeiraGTx Holdings plc

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2026, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026, with a term that expires at the Company’s 2028 annual meeting of shareholders when Class I directors are up for re-election and until his successor is duly elected and qualified. Mr. Sebulsky has been appointed to serve as a member of the Science and Technology Committee. Mr. Sebulsky was recommended as a potential candidate for election to our Board by the Company’s senior management. Mr. Sebulsky has served as the Managing Member of Apothecary Capital LLC since its reestablishment in April 2026. Mr. Sebulsky previously served as a Partner and Portfolio Manager at Adage Capital Management, LP. from July 2012 to April 2026, where he was responsible for managing a biopharmaceutical portfolio. Prior to that Mr. Sebulsky served as a Portfolio Manager at BBT Capital Management Advisory LLC from April 2003 to March 2012, through his role as the Managing Partner of Apothecary Capital LLC over the same period. From 1994 to 2002, Mr. Sebulsky held various positions, including as a Managing Director at Lincoln Capital Management, a private investment management firm, where he was responsible for investments in the healthcare industry. Mr. Sebulsky currently serves as a member of the board of directors of Parabilis Medicines, Inc and previously served on the boards of directors of Jazz Pharmaceuticals PLC and Arrow International, Inc. Mr. Sebulsky received a B.B.A. in finance and economics and an M.S. in finance from the University of Wisconsin, Madison. Mr. Sebulsky will be eligible to receive compensation for his service as a member of the Board pursuant to the terms of the Company’s Non-Employee Director Compensation Program, as amended from time to time. We expect that Mr. Sebulsky will enter into the Company’s standard form of indemnification agreement for its directors and officers. Mr. Sebulsky was not selected as a director pursuant to any arrangement or understanding between him and any other person. There are no related party transactions between the Company and Mr. Sebulsky.

Item 7.01. Regulation FD Disclosure. On September 23, 2026, the Company issued a press release announcing the appointment of Alan M. Sebulsky to the Board, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.